GLP-1 Without a BMI of 30: What Qualifies You

See if you qualify — takes about 5 minutes →
5-minute questionnaire · reviewed by a licensed clinician · The Nouri Promise: 30-day full refund on 3-month and 6-month plans · cancel anytime

BMI and GLP-1 eligibility at a glance

Your BMI	With a weight-related condition	Without one
BMI ≥ 30	Qualifies	Qualifies (no condition needed)
BMI 27–29.9	Generally qualifies	Generally does not qualify
BMI under 27	Generally does not qualify	Does not qualify

Eligibility is confirmed by a licensed clinician based on your individual history. Information current as of June 2026; approval thresholds are set in the FDA label for each medication.

How do you qualify for a GLP-1 at BMI 27–29.9?

The path to qualifying at a BMI between 27 and 30 is a weight-related condition. The conditions specifically named in the Wegovy FDA label are high blood pressure, type 2 diabetes, high cholesterol, obstructive sleep apnea, and cardiovascular disease. If you have one of these, BMI 27+ meets the approved threshold.

Prediabetes and polycystic ovary syndrome (PCOS) are not named in the FDA labels but may be considered by a clinician as part of an individual assessment. What matters is the full clinical picture, not a single number.

The NIDDK summarizes the same thresholds: BMI ≥ 30, or ≥ 27 with at least one weight-related condition, for FDA-approved weight-management medications.

Why does a weight-related condition matter at lower BMI?

The BMI thresholds reflect where the clinical benefit-to-risk calculation clearly favors treatment. A pivotal weight-management trial of semaglutide 2.4 mg (STEP 1, published in NEJM) enrolled adults with BMI ≥ 27 and a weight-related comorbidity — enrolling this group because the comorbidities mark the patients most likely to benefit. Wilding et al., NEJM 2021

A subsequent cardiovascular outcomes trial (SELECT, NEJM 2023) showed semaglutide reduced major adverse cardiovascular events in people with overweight or obesity and pre-existing cardiovascular disease — the same population the BMI 27+ comorbidity standard targets. Lincoff et al., NEJM 2023

These are studies of the branded molecules (semaglutide), not of compounded semaglutide or of any specific program's outcomes.

Can you get a GLP-1 without diabetes?

Yes — this is a common misconception. Diabetes is simply one of several conditions that can qualify you at a lower BMI; it is not required. The weight-loss GLP-1s (Wegovy, Zepbound) are approved for chronic weight management based on BMI and weight-related conditions. High blood pressure alone is sufficient if your BMI is 27 or higher.

What if you don't qualify?

If your BMI is under 27, or is 27–29.9 with no qualifying condition, a GLP-1 is generally not FDA-approved for you, and a responsible clinician won't prescribe it. That's a sign of a trustworthy program, not a barrier to be worked around. Per the FDA, compounded versions of GLP-1 medications are also subject to the same prescribing standards — a valid clinical indication is required.

If you are close to the threshold, a clinician can review your full history — including conditions like prediabetes that aren't listed in the label but may be clinically relevant — and discuss evidence-based options appropriate for your profile.

For a broader look at whether you meet the criteria, see our GLP-1 eligibility guide. If you only have a small amount of weight to lose, this article covers that scenario honestly.

How Nouri works

Nouri is a telehealth program designed to make the legitimate path easy. You complete a 5-minute online questionnaire; a U.S.-licensed clinician reviews your file — a real evaluation, with a video visit where your state requires one — and, if appropriate, your therapy ships discreetly from a named, state-licensed 503A pharmacy (Jungle Jim's Pharmacy, Fairfield OH). Nouri is LegitScript-certified, available in all 50 states, and includes a personalized nutrition plan, a movement plan, and unlimited concierge care.

The Program is all-inclusive at one price. Compounded semaglutide plans start at $120/month on the 6-month plan ($720 billed every 6 months), $145/month on the 3-month plan ($435 every 3 months), or $175/month billed monthly. Compounded tirzepatide starts at $175/month on the 6-month plan ($1,050 every 6 months), $199/month on the 3-month plan ($597 every 3 months), or $225/month billed monthly. Any dose, same price. For full plan details see our GLP-1 cost breakdown.

Your start is backed by The Nouri Promise: if you're not satisfied in your first 30 days, you get a full refund — available on 3-month and 6-month plans.

Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not the same as, or therapeutically equivalent to, brand-name drugs such as Wegovy, Ozempic, Zepbound, or Mounjaro.

Start your 5-minute assessment →
5-minute questionnaire · reviewed by a licensed clinician · 30-day full refund on 3-month and 6-month plans · cancel anytime

Related getting-started guides

• Do You Qualify for a GLP-1? (eligibility hub)
• How Online GLP-1 Programs Work
• GLP-1 If You Only Have a Little to Lose
• How to Get Semaglutide Online

Frequently asked questions

Can you get a GLP-1 without obesity?

Yes — at a BMI of 27–29.9 if you also have a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or sleep apnea. Without a qualifying condition in that BMI range, you generally don't meet the FDA-approved threshold.

Can I get Ozempic without diabetes?

For weight loss you don't need diabetes. The weight-loss GLP-1s (Wegovy, Zepbound) are approved based on BMI and weight-related conditions. Ozempic is the diabetes brand; for weight loss the on-label option is Wegovy. Compounded semaglutide is prescribed for weight management under the same clinical criteria.

What conditions qualify you at BMI 27?

High blood pressure, type 2 diabetes, high cholesterol, obstructive sleep apnea, and cardiovascular disease are named in the FDA labels. Prediabetes and PCOS aren't named in the labels but may be considered by a clinician as part of an individual evaluation.

Do you need a BMI of 30 for semaglutide?

Not necessarily. A BMI of 27 or higher qualifies if you have a weight-related condition. A BMI of 30 qualifies on its own. Below those thresholds, a GLP-1 generally isn't approved.

Can you get a GLP-1 at a BMI of 27?

At a BMI of 27 you can qualify only if you also have a weight-related condition such as high blood pressure or sleep apnea. Without a qualifying condition at BMI 27, you generally don't meet the threshold — and a clinician who prescribes without one isn't following standard guidelines.

Does sleep apnea or high blood pressure qualify me?

Yes. Obstructive sleep apnea and high blood pressure are both weight-related conditions explicitly named in the FDA labels, so either can qualify you at a BMI of 27 or higher.

Sources & references

1. Wegovy (semaglutide) FDA prescribing label — BMI ≥ 27 with comorbidity threshold (FDA, 2025). Tier 1.
2. Prescription medications to treat overweight and obesity (NIDDK/NIH). Tier 1.
3. Human drug compounding (FDA). Tier 1.
4. FDA: concerns with unapproved GLP-1 drugs used for weight loss (FDA). Tier 1.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM 2021. (Research on semaglutide 2.4 mg, not on Nouri's compounded product.) Tier 1.
6. Lincoff AM et al. Semaglutide and cardiovascular outcomes in overweight or obese people without diabetes (SELECT). NEJM 2023. (Research on semaglutide, not on Nouri's compounded product.) Tier 1.
7. FDA BeSafeRx: buying medicine online safely (FDA). Tier 1.

Medically reviewed by Amber Patel, MD. Author: Nouri Editorial Team. Nouri content is reviewed by licensed clinicians and updated as guidance changes.

This article is general education, not medical advice — eligibility and prescribing decisions are made by a licensed clinician based on your individual evaluation. Ozempic® and Wegovy® are registered trademarks of Novo Nordisk; Mounjaro® and Zepbound® are registered trademarks of Eli Lilly; Nouri is not affiliated with, endorsed by, or sponsored by these companies. Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as, or therapeutically equivalent to, the brand-name drugs. Telehealth prescribing requirements vary by state and may change. Information is current as of June 2026.